bioRxivCell BiologyPreprint
The dual PPAR-α/δ agonist elafibranor attenuates TGF-β1-induced cardiac fibrosis through redox-metabolic and bioenergetic reprogramming in human cardiac models
Milena PawiD, Lukas MinderiD, Andrea LaimbacheriD, Magdalena CzepieciD, Sylwia Bobis‐WozowicziD, Dawid WnukiD, Barbara Anna Kutryb-ZająciD, Alicja BraczkoiD, Michał SarnaiD, Patrycja KaczaraiD, Stefan ChłopickiiD, Zbigniew MadejaiD, Oliver DistleriD, Przemysław BłyszczukiD, Jarosław CzyżiD, Gabriela KaniaiD
Abstract
BackgroundCardiac fibrosis drives adverse myocardial remodelling through persistent fibroblast activation, ECM deposition, and impaired cardiac function. Current therapies offer limited protection against cardiac fibrosis progression. Elafibranor is a dual PPAR-/{delta} agonist approved for the treatment of liver disease. However, its effects in human models of cardiac fibrosis remain insufficiently explored. MethodsElafibranor was evaluated in complementary human in vitro TGF-{beta}1-induced cardiac fibrosis models: 2D primary fibroblasts, 3D fibroblast spheroids, spontaneously contracting 3D cardiac microtissues, and hiPSC-derived cardiomyocytes. Viability, apoptosis, fibroblast activation, ECM remodelling, mitochondrial respiration, nucleotide and NAD pools, calcium handling, contractility, and transcriptomic profiles were assessed. ResultsAt non-cytotoxic concentrations, elafibranor attenuated TGF-{beta}1-driven cardiac fibrosis responses. In 2D cardiac fibroblasts, it reduced myofibroblast differentiation, procollagen 11 secretion, and partially restored mitochondrial respiratory capacity. In 3D spheroids, it preserved viability, attenuated caspase-3/7 activation, and suppressed procollagen 11 release. In cardiac microtissues, elafibranor reduced ECM accumulation, shifted transcriptomic profiles toward redox-metabolic/cytoprotective pathways, altered adenine nucleotide and NAD pools, and partially recovered contraction parameters. In hiPSC-derived cardiomyocytes, elafibranor modulated calcium handling, contractility, and mitochondrial respiration. ConclusionsElafibranor mitigates TGF-{beta}1-driven cardiac fibrosis by suppressing fibroblast activation and ECM remodelling while promoting adaptive metabolic, redox, and bioenergetic responses, supporting balanced PPAR-/{delta} activation as a potential therapeutic strategy for cardiac fibrosis. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=142 SRC="FIGDIR/small/745425v1_ufig1.gif" ALT="Figure 1"> View larger version (54K): org.highwire.dtl.DTLVardef@2de670org.highwire.dtl.DTLVardef@173fea6org.highwire.dtl.DTLVardef@537e7aorg.highwire.dtl.DTLVardef@194b846_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lanifibranor (IVA-337) - a pan-PPAR agonist suppresses TGF-β1-induced cardiac fibrosis and rescues cardiomyocyte function
Milena Paw, Lukas Minder, … Gabriela Kania·bioRxiv·Aug 21, 2026
- FAM114A1 Influences Cardiac Fibrosis by Regulating Angiotensin II Signaling in Cardiac Fibroblasts
K. C. V. Subbaiah, J. Wu, … P. Yao·bioRxiv·Feb 20, 2021
- Cardiomyocyte-restricted expression of IL11 causes cardiac fibrosis, inflammation, and dysfunction.
Mark D. Sweeney, Katie O’Fee, … Stuart A. Cook·International Journal of Molecular SciencesPeer-reviewed·Aug 20, 2023
- Effects of Emodin, a Plant-Derived Anthraquinone, on TGFβ1-Induced Cardiac Fibroblast Activation and Function
M. Azhar, W. Carver, … M. Chakrabarti·bioRxiv·Jan 7, 2021
- Consequences of PDGFRα+ fibroblast reduction in adult murine hearts
J. T. Kuwabara, S. Bhutada, … M. D. Tallquist·bioRxiv·May 7, 2021
- Logic-based mechanistic machine learning on high-content images reveals how drugs differentially regulate cardiac fibroblasts
Anders R. Nelson, Steven L. M. Christiansen, … Jeffrey J. Saucerman·Proceedings of the National Academy of SciencesPeer-reviewed·Jan 24, 2024